Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: A multicenter, open-label, Phase II trial.
Conclusions Surufatinib demonstrated promising efficacy with a tolerable and manageable safety profile for patients with locally advanced or metastatic MTC, RAI-refractory DTC, or locally advanced, unresectable recurrences unable to receive RAI.
PMID: 32075524 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Endocrinology | Hypertension | Proteinuria | Study | Thyroid | Thyroid Cancer